Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cis-diamminedichloroplatinum · 1 trial · 1 indication
Adverse events as defined using the Common Terminology Criteria for Adverse Events
| Arm | Type | Description |
|---|---|---|
| Intratumoral Cisplatin 20 mg | EXPERIMENTAL | Second dose level |
| Intratumoral Cisplatin 10 mg | EXPERIMENTAL | First dose level |
| Name | Type | Description |
|---|---|---|
| cis-diamminedichloroplatinum | DRUG | Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC |
Inclusion Criteria: * Age ≥18 years. * Eastern Cooperative Oncology Group performance status 0 or 1 * Patients must have adequate organ and marrow function as defined below: * Leukocytes ≥3,000/microliter * Platelets ≥100,000/microliter * Total bilirubin ≤ institutional upper limit of normal...
Top 20 of 84 competitors
Cis-diamminedichloroplatinum is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer. It is administered intratumorally in a clinical trial for patients with resectable NSCLC. The drug is in Phase 1 development and is not yet approved by regulatory authorities.
Cis-diamminedichloroplatinum is a platinum-based small molecule that works by forming crosslinks within DNA, which disrupts DNA replication and transcription, leading to cancer cell death. This mechanism is being evaluated in the context of Non-Small Cell Lung Cancer in an ongoing clinical development program.
Cis-diamminedichloroplatinum is being developed by Johnson & Johnson, a company publicly traded under the ticker JNJ. The drug is currently in Phase 1 clinical development for Non-Small Cell Lung Cancer, with one completed trial involving six participants.
Cis-diamminedichloroplatinum is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The Phase 1 trial for Non-Small Cell Lung Cancer has been completed, and the drug remains under clinical investigation.
Cis-diamminedichloroplatinum has one completed clinical trial registered under NCT04809103, titled "Intratumoral Cisplatin for Resectable NSCLC." This Phase 1 study enrolled six participants with Non-Small Cell Lung Cancer in the United States, with a minimum age of 18 years and no healthy volunteers.